On February 13, 2026, First Turn Management, LLC announced in an SEC filing that it sold all 313,733 shares of Arcellx (NASDAQ: ACLX), resulting in a transaction valued at approximately $25.76 million. This sale contributed to a decrease in the fund’s quarter-end position in Arcellx, reflecting both the sale and fluctuations in the share price. Arcellx is a clinical-stage biotechnology firm focused on developing innovative cell-based immunotherapies for cancer, addressing significant unmet medical needs. The company employs proprietary technology platforms to advance its diverse pipeline targeting hematologic malignancies and solid tumors.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
